Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Nanobiotix ( (NBTX) ) just unveiled an announcement.
Nanobiotix is set to host a virtual event on December 19, 2024, to introduce its vision for the next generation of nanotherapeutic platforms. The event will highlight the Curadigm Nanoprimer Platform, which aims to transform drug design and development for intravenously-administered therapeutics by increasing drug bioavailability and reducing liver toxicity. This initiative could significantly enhance treatment outcomes for patients, solidifying Nanobiotix’s position as a leader in innovative nanotechnology solutions.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company, based in Paris and listed on Euronext Paris and Nasdaq. The company specializes in nanoparticle-based therapeutic approaches, focusing on oncology, bioavailability, biodistribution, and disorders of the central nervous system. With over 25 umbrella patents, Nanobiotix aims to revolutionize treatment outcomes for millions of patients globally.
YTD Price Performance: -52.06%
Average Trading Volume: 22,227
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $165.2M
Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.
